Now is Our Opportunity to Revolutionise Cancer Clinical Trials
Clin Oncol (R Coll Radiol)
.
2023 Mar;35(3):139-142.
doi: 10.1016/j.clon.2022.10.018.
Epub 2022 Nov 18.
Authors
J Bliss
1
,
J Brown
2
,
A Chalmers
3
,
N Lemoine
4
,
G Murphy
5
,
K Wydenbach
6
,
I Frame
5
Affiliations
1
The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. Electronic address: Judith.bliss@icr.ac.uk.
2
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, LS29JT, UK.
3
University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK.
4
NIHR Clinical Research Network Coordinating Centre, Minerva House, 5 Montague Cl, London, SE1 9DF, UK.
5
National Cancer Research Institute (NCRI), 2 Redman Place, London, E20 1JQ, UK.
6
Medicines and Healthcare Products Regulatory Agency, 10 South Colonnade, Canary Wharf, London, E14 4PU, UK.
PMID:
36411142
DOI:
10.1016/j.clon.2022.10.018
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
MeSH terms
Clinical Trials as Topic*
Humans
Neoplasms* / therapy
Grants and funding
25351/CRUK_/Cancer Research UK/United Kingdom
25447/CRUK_/Cancer Research UK/United Kingdom